Melanoma biology and new targeted therapy

[1]  L. Senelick.  It (review) , 2008 .

[2]  M. Gordon.  Tumor Necrosis Factor-α Blocks Apoptosis in Melanoma Cells when BRAF Signaling Is Inhibited , 2008 .

[3]  H. Pehamberger,et al.  Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Rosenberg,et al.  Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes , 2006, Science.

[5]  C. Springer,et al.  In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. , 2006, Cancer research.

[6]  D. Fisher,et al.  MITF: master regulator of melanocyte development and melanoma oncogene. , 2006, Trends in molecular medicine.

[7]  J. Dancey.  Therapeutic targets: MTOR and related pathways , 2006, Cancer biology & therapy.

[8]  M. Ratain,et al.  Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis , 2006, British Journal of Cancer.

[9]  R. Marais,et al.  Cellular senescence in naevi and immortalisation in melanoma: a role for p16? , 2006, British Journal of Cancer.

[10]  N. Normanno,et al.  Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. , 2006, The oncologist.

[11]  L. Chin,et al.  Comparative Oncogenomics Identifies NEDD9 as a Melanoma Metastasis Gene , 2006, Cell.

[12]  C. Cooke,et al.  Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma , 2006, Oncogene.

[13]  L. Cantley,et al.  Ras, PI(3)K and mTOR signalling controls tumour cell growth , 2006, Nature.

[14]  Keith T Flaherty,et al.  Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases , 2006, Molecular Cancer Therapeutics.

[15]  S. Hirono,et al.  Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. , 2006, Journal of the National Cancer Institute.

[16]  J. Hansson,et al.  Mutations of PIK3CA are rare in cutaneous melanoma , 2006, Melanoma research.

[17]  K. Flaherty.  Chemotherapy and Targeted Therapy Combinations in Advanced Melanoma , 2006, Clinical Cancer Research.

[18]  J. Kirkwood,et al.  Strategies for the Development of More Effective Adjuvant Therapy of Melanoma: Current and Future Explorations of Antibodies, Cytokines, Vaccines, and Combinations , 2006, Clinical Cancer Research.

[19]  G. Tucker.  Integrins: Molecular targets in cancer therapy , 2006, Current oncology reports.

[20]  J. Schmid,et al.  BMS-345541 Targets Inhibitor of κB Kinase and Induces Apoptosis in Melanoma: Involvement of Nuclear Factor κB and Mitochondria Pathways , 2006, Clinical Cancer Research.

[21]  Todd R. Golub,et al.  BRAF mutation predicts sensitivity to MEK inhibition , 2006, Nature.

[22]  N. Rosen,et al.  V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Agarwala,et al.  Cutaneous melanoma: available therapy for metastatic disease , 2006, Dermatologic therapy.

[24]  O. M. Grbovic,et al.  V600E B‐Rafはその安定性にHsp90シャペロンを要求し,Hsp90阻害剤への応答として分解される , 2006 .

[25]  S. Wilhelm,et al.  Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. , 2006, Methods in enzymology.

[26]  Paul Workman,et al.  Inhibitors of the HSP90 molecular chaperone: current status. , 2006, Advances in cancer research.

[27]  D. Barford,et al.  Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. , 2005, Molecular cell.

[28]  P. Workman,et al.  Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. , 2005, Cancer research.

[29]  J. Fridlyand,et al.  Distinct sets of genetic alterations in melanoma. , 2005, The New England journal of medicine.

[30]  R. Marais,et al.  Elevated expression of MITF counteracts B-RAF–stimulated melanocyte and melanoma cell proliferation , 2005, The Journal of cell biology.

[31]  J. Shay,et al.  BRAFE600-associated senescence-like cell cycle arrest of human naevi , 2005, Nature.

[32]  T. Golub,et al.  Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma , 2005, Nature.

[33]  P. LoRusso,et al.  A phase II study of bortezomib in the treatment of metastatic malignant melanoma , 2005, Cancer.

[34]  A. Trumpp,et al.  Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. , 2005, Cancer research.

[35]  A. Aplin,et al.  Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF-MEK-ERK signaling , 2005, Oncogene.

[36]  S. Tripp,et al.  Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. , 2005, Human pathology.

[37]  D. Tuveson,et al.  Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. , 2005, Cancer research.

[38]  D. Fisher,et al.  Mechanisms of Hair Graying: Incomplete Melanocyte Stem Cell Maintenance in the Niche , 2005, Science.

[39]  M. Herlyn,et al.  The Role of Altered Cell–Cell Communication in Melanoma Progression , 2003, Journal of Molecular Histology.

[40]  R. Weinberg,et al.  The evolving portrait of cancer metastasis. , 2005, Cold Spring Harbor symposia on quantitative biology.

[41]  R. Marais,et al.  The role of B-RAF in melanoma , 2005, Cancer and Metastasis Reviews.

[42]  J. Doroshow,et al.  CCI‐779 in metastatic melanoma , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[43]  Richard Marais,et al.  The RAF proteins take centre stage , 2004, Nature Reviews Molecular Cell Biology.

[44]  N. Pryer,et al.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.

[45]  M. Robinson,et al.  Kinase Mitogen-activated Protein Kinase Tpl-2/mek/extracellular Signal-regulated Lipopolysaccharide Activation of the Supplemental Material , 2004 .

[46]  D. Auclair,et al.  BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis , 2004, Cancer Research.

[47]  D. Tobin,et al.  Melanin pigmentation in mammalian skin and its hormonal regulation. , 2004, Physiological reviews.

[48]  J. Cheng,et al.  Deregulated Akt3 Activity Promotes Development of Malignant Melanoma , 2004, Cancer Research.

[49]  C. Der,et al.  Overexpression of Collagenase 1 (MMP-1) Is Mediated by the ERK Pathway in Invasive Melanoma Cells , 2004, Journal of Biological Chemistry.

[50]  Ann Richmond,et al.  Augmenting Chemosensitivity of Malignant Melanoma Tumors via Proteasome Inhibition , 2004, Cancer Research.

[51]  P. Guldberg,et al.  Genetic and epigenetic alterations of the APC gene in malignant melanoma , 2004, Oncogene.

[52]  G. Karczmar,et al.  Phase II Study of the Flk-1 Tyrosine Kinase Inhibitor SU5416 in Advanced Melanoma , 2004, Clinical Cancer Research.

[53]  C. Springer,et al.  V599EB-RAF is an Oncogene in Melanocytes , 2004, Cancer Research.

[54]  R. Marais,et al.  The Brn-2 Transcription Factor Links Activated BRAF to Melanoma Proliferation , 2004, Molecular and Cellular Biology.

[55]  F. Haluska,et al.  Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. , 2004, The Journal of investigative dermatology.

[56]  J. Doroshow,et al.  CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. , 2004, Cancer.

[57]  Gang Li,et al.  The role of Bcl-2 family members in the progression of cutaneous melanoma , 2004, Clinical & Experimental Metastasis.

[58]  C. Springer,et al.  Advances in Brief V 599 EB-RAF is an Oncogene in Melanocytes , 2004 .

[59]  M. Scarsella,et al.  Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity , 2003, Oncogene.

[60]  D. Fisher,et al.  SKI Activates Wnt/-Catenin Signaling in Human Melanoma1 , 2003 .

[61]  E. Collisson,et al.  Treatment of metastatic melanoma with an orally available inhibitor of the Ras-Raf-MAPK cascade. , 2003, Cancer research.

[62]  S. Lowe,et al.  Rb-Mediated Heterochromatin Formation and Silencing of E2F Target Genes during Cellular Senescence , 2003, Cell.

[63]  K. Smalley,et al.  Farnesyl transferase inhibitor SCH66336 is cytostatic, pro‐apoptotic and enhances chemosensitivity to cisplatin in melanoma cells , 2003, International journal of cancer.

[64]  S. Lowe,et al.  Apoptosis and melanoma chemoresistance , 2003, Oncogene.

[65]  N. Hayward.  Genetics of melanoma predisposition , 2003, Oncogene.

[66]  F. Haluska,et al.  PTEN signaling pathways in melanoma , 2003, Oncogene.

[67]  L. Chin,et al.  The INK4a/ARF locus and melanoma , 2003, Oncogene.

[68]  D. Bennett.  Human melanocyte senescence and melanoma susceptibility genes , 2003, Oncogene.

[69]  D. Elder,et al.  Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. , 2003, Cancer research.

[70]  D. Weiss,et al.  Mutational analysis of N-ras, p53, CDKN2A (p16INK4a), p14ARF, CDK4, and MC1R genes in human dysplastic melanocytic naevi , 2003, Journal of medical genetics.

[71]  James R. Burke,et al.  BMS-345541 Is a Highly Selective Inhibitor of IκB Kinase That Binds at an Allosteric Site of the Enzyme and Blocks NF-κB-dependent Transcription in Mice* , 2003, The Journal of Biological Chemistry.

[72]  P. Meltzer,et al.  High frequency of BRAF mutations in nevi , 2003, Nature Genetics.

[73]  J. Arbiser,et al.  Mitogen-actived protein kinase activation is an early event in melanoma progression. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[74]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[75]  D. Pinkel,et al.  Cyclin D1 is a candidate oncogene in cutaneous melanoma. , 2002, Cancer research.

[76]  H. Pehamberger,et al.  The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. , 2002, Cancer research.

[77]  G. Woude,et al.  Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[78]  M. Schartl,et al.  Activation of p59Fyn Leads to Melanocyte Dedifferentiation by Influencing MKP-1-regulated Mitogen-activated Protein Kinase Signaling* , 2002, The Journal of Biological Chemistry.

[79]  D. Polsky,et al.  The transcriptional repressor of p16/Ink4a, Id1, is up-regulated in early melanomas. , 2001, Cancer research.

[80]  J. Hansson,et al.  Cytoplasmic and nuclear accumulation of β‐catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma , 2001, International journal of cancer.

[81]  T. Saida,et al.  Updated statistical data for malignant melanoma in Japan , 2001, International Journal of Clinical Oncology.

[82]  W. Gerald,et al.  Inactivation of the apoptosis effector Apaf-1 in malignant melanoma , 2001, Nature.

[83]  C. Bowden,et al.  Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. , 2001, Cancer research.

[84]  E. Rofstad,et al.  Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. , 2000, Cancer research.

[85]  T. N. Campbell,et al.  Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin alphavbeta3. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[86]  C. Garbe,et al.  Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients , 2000, The British journal of dermatology.

[87]  Kazuhiro Takahashi,et al.  Induction of Melanocyte-specific Microphthalmia-associated Transcription Factor by Wnt-3a* , 2000, The Journal of Biological Chemistry.

[88]  E. Price,et al.  c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. , 2000, Genes & development.

[89]  D. Hanahan,et al.  The Hallmarks of Cancer , 2000, Cell.

[90]  L. Chin,et al.  Essential role for oncogenic Ras in tumour maintenance , 1999, Nature.

[91]  D. Rimm,et al.  Frequent nuclear/cytoplasmic localization of beta-catenin without exon 3 mutations in malignant melanoma. , 1999, The American journal of pathology.

[92]  T. Mack,et al.  The pathogenesis of melanoma induced by ultraviolet radiation. , 1999, The New England journal of medicine.

[93]  H. Pehamberger,et al.  bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice , 1998, Nature Medicine.

[94]  L. Akslen,et al.  Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma , 1997, International journal of cancer.

[95]  J. Nordlund,et al.  Molecular basis of congenital hypopigmentary disorders in humans: a review. , 1997, Pigment cell research.

[96]  U. Ringborg.  Review: Cutaneous Malignant Melanoma , 1996 .

[97]  R. Halaban,et al.  Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes. , 1995, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[98]  G. Hannon,et al.  A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4 , 1993, Nature.

[99]  D. Gale.  MOLECULAR TARGETS FOR CANCER THERAPY , 1990, The Lancet.

[100]  M. N. Epstein,et al.  A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. , 1984, Human pathology.

[101]  M. Uslenghi,et al.  The World Space Observatory (WSO-UV) - Current status , 2008, 0801.2080.